Successful treatment with recombinant soluble thrombomodulin of two cases of sinusoidal obstructive syndrome/hepatic veno-occlusive disease after bone marrow transplantation

American Journal of Hematology

Volumn 86, Issue 10, 2011, Pages 886-888

  Ohwada, Chikako ^a   Takeuchi, Masahiro ^a   Kawaguchi, Takeharu ^a   Tsukamoto, Shokichi ^a   Sakai, Shio ^a   Takeda, Yusuke ^a   Abe, Daijiro ^a   Sakaida, Emiko ^a   Shimizu, Naomi ^a   Yokote, Koutaro ^b   Iseki, Tohru ^a   Nakaseko, Chiaki ^a  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FIBRIN DEGRADATION PRODUCT; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISOLONE; PROTHROMBIN; RECOMBINANT SOLUBLE THROMBOMODULIN; RECOMBINANT THROMBOMODULIN; TACROLIMUS; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG MEGADOSE; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; HEPATIC SINUSOIDAL OBSTRUCTIVE SYNDROME; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; LIVER VEIN OBSTRUCTION; LYMPHOBLASTOMA; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

ADULT; BONE MARROW TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; MIDDLE AGED; THROMBOMODULIN;

EID: 80052877711     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22137     Document Type: Letter

References (19)

1. McDonald GB, Sharma P, Matthews DE, et al. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
2. Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: Incidence, clinical course and outcome. Biol Blood Marrow Transplant 2010; 16: 157-168.
3. Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003; 78: 589-598.
4. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2008; 41: 229-237.
5. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5: 31-41.
6. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115: 1267-1274.
7. Pihusch M, Wegner H, Goehring P, et al. Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: A prospective analysis in 350 allogeneic hematopoietic stem cell recipients. Transplantation 2005; 80: 1376-1382.
8. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337-4343.
9. Bulley SR, Strahm B, Doyle J, Dupuis LL. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer 2007; 48: 700-704.
10. Richardson PG, Soiffer RJ, Antin JH, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multi-organ failure post stem cell transplantation: A multi-center, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010; 16: 1005-1017.
11. Haussmann U, Fischer J, Eber S, et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: Impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 2006; 91: 795-800.
12. Nagato M, Okamoto K, Abe Y, et al. Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med 2009; 37: 2181-2186.
13. Ito T, Kawahara K, Okamoto K, et al. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 2008; 28: 1825-1830.
14. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
15. Hatada T, Wada H, Nobori T, et al. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005; 94: 975-979.
16. Ikezoe T, Togitani K, Komatsu N, et al. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45: 783-785.
17. Sakai M, Ikezoe T, Bandobashi K, et al. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45: 803-805.
18. Shi CS, Shi GY, Hsiao SM, et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008; 112: 3661-3670.
19. Tsubokura M, Yamashita T, Inagaki L, et al. Fatal intracranial hemorrhage following administration of recombinant thrombomodulin in a patient after cord blood transplantation. Bone Marrow Transplant 2011; 46: 1030-1031.